## **DBCG – SKAGEN TRIAL 1**

## PATHOLOGY REPORT

DANISH BREAST CANCER COOPERATIVE GROUP

Name – Patient ID		Hospital
Day Month Year	No.	

## Pathology report on patients included in the Skagen Trial 1

Date of last surgery	Size of invasive carcinoma					
Surgical type   Mastectomy Lumpectomy			Resection margin from invas carcinoma (mm)			
Axillary lymph node dissection			If DCIS present: Resection margin from DCIS			
Number of lymph nodes (LNs) removed in total			Type of invasive carcinoma	Duct Lobu Othe	ular	
Number of LNs with macrometastases			Malignancy grade			l lot graded
Number of LNs with micrometastases			ER status (%)			
Sentinel node biopsy used	□ No □ Yes		Ki67 (%)			
Number of sentinel nodes			HER2 status	□ Norn □ Posi		

## Neoadjuvant or primary systemic therapy

Clini	Clinical stage before neoadjuvant or primary systemic therapy according to AJCC										
сТ	□ 1	□ 2	□ 3	□ 4	□ 4a	□ 4b	□ 4c	□ 4d	□ X (unknown)		
cN	□ 0	□ 1	□ 2	□ 3	🛛 X (un	known)					

Response of the primary tumour to neoadjuvant/primary systemic therapy	<ul> <li>□ Grade 1 = No invasive cancer cells (presence of DCIS is allowed)</li> <li>□ Grade 2 = More than 90% loss of cancer cells</li> <li>□ Grade 3 = Between 30 and 90% loss of cancer cells</li> <li>□ Grade 4 = Less than 30% loss of cancer cells</li> </ul>
--	---

Response to neoadjuvant/primary systemic therapy in the axilla				
Number of LNs with metastases and sign of response to therapy				
Number of LNs without metastases and with sign of response to therapy				

Form filled in by: Name:					
(CAPITAL LETTERS)					
Sign.:	Date				ddmmyy